EuroQol (EQ-5D) health utility scores for patients with migraine

被引:47
作者
Xu, Ruifeng [1 ,2 ]
Insinga, Ralph P. [2 ]
Golden, Wendy [3 ]
Hu, X. Henry [3 ]
机构
[1] Merck & Co Inc, N Wales, PA 19454 USA
[2] Merck Res Labs, Dept Hlth Econ Stat, N Wales, PA USA
[3] Merck & Co Inc, Global Human Hlth, Global Outcomes Res & Reimbursement, Whitehouse Stn, NJ USA
关键词
Migraine; Headache; EQ-5D; Health utility score; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; CHRONIC MEDICAL CONDITIONS; UNITED-STATES; INDEX SCORES; PROPHYLACTIC TREATMENT; AMERICAN MIGRAINE; DOUBLE-BLIND; POPULATION; TOPIRAMATE;
D O I
10.1007/s11136-010-9783-5
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Previous studies have reported health utilities for migraine patients as generally measured between migraine attacks, but health utility data for within a migraine attack are unavailable. We evaluated within-attack health utilities among acute migraine patients experiencing different grades of headache severity. We examined data for 330 20-65-year-old adults, in good physical health, who had 1-6 moderate/severe migraine attacks per month in the 2 months prior to the screening visit. Data were collected from a multicenter, double-blind study of a treatment for acute migraine in the United States. The EQ-5D system was used to measure generic health status at baseline and 24 h post-treatment within an acute migraine attack, and patients were also asked to rate their pain level at these time points (no, mild, moderate, or severe pain). The D1 time-trade-off scoring algorithm for the U.S. population was applied. Confidence intervals were estimated by bootstrap methods. The study population was 88% women and 78% white ethnicity, with 60% of subjects over age 40. The disutility of mild migraine pain was estimated to be 0.140 (95% CI: 0.0848, 0.1940), with a disutility for moderate migraine pain of 0.186 (95% CI: 0.1645, 0.2053) and for severe migraine pain of 0.493 (95% CI: 0.4100, 0.5654). Within-attack disutilities estimated for migraine in this study are much greater than those reported for migraine when evaluated as a chronic health condition (e.g., valuations collected at random time points). These data can be of value in adapting results from clinical trials of migraine interventions to cost-utility policy analyses.
引用
收藏
页码:601 / 608
页数:8
相关论文
共 37 条
[21]   A comparison of visual analog scale and categorical ratings of headache pain in a randomized controlled clinical trial with migraine patients [J].
Lines, CR ;
Vandormael, K ;
Malbecq, W .
PAIN, 2001, 93 (02) :185-190
[22]   Migraine diagnosis and treatment: Results from the American Migraine Study II [J].
Lipton, RB ;
Diamond, S ;
Reed, M ;
Diamond, ML ;
Stewart, WF .
HEADACHE, 2001, 41 (07) :638-645
[23]   Prevalence and burden of migraine in the United States: Data from the American Migraine Study II [J].
Lipton, RB ;
Stewart, WF ;
Diamond, S ;
Diamond, ML ;
Reed, M .
HEADACHE, 2001, 41 (07) :646-657
[24]   Relative Efficiency of the EQ-5D, HUI2, and HUI3 Index Scores in Measuring Health Burden of Chronic Medical Conditions in a Population Health Survey in the United States [J].
Luo, Nan ;
Johnson, Jfrey A. ;
Shaw, James W. ;
Coons, Stephen Joel .
MEDICAL CARE, 2009, 47 (01) :53-60
[25]   Utility scores for chronic conditions in a community-dwelling population [J].
Mittmann, N ;
Trakas, K ;
Risebrough, N ;
Liu, BA .
PHARMACOECONOMICS, 1999, 15 (04) :369-376
[26]  
Mo Frank, 2004, ScientificWorldJournal, V4, P746
[27]   Psychometric comparison of the standard EQ-5D to a 5 level version in cancer patients [J].
Pickard, A. Simon ;
De Leon, Maria C. ;
Kohlmann, Thomas ;
Cella, David ;
Rosenbloom, Sarah .
MEDICAL CARE, 2007, 45 (03) :259-263
[28]   The impact of 29 chronic conditions on health-related quality of life:: A general population survey in finland using 15D and EQ-5D [J].
Saarni, Samuli I. ;
Harkanen, Tommi ;
Sintonen, Harri ;
Suvisaari, Jaana ;
Koskinen, Seppo ;
Aromaa, Arpo ;
Lonnqvist, Jouko .
QUALITY OF LIFE RESEARCH, 2006, 15 (08) :1403-1414
[29]   Prophylactic treatment of migraine with angiotensin converting enzyme inhibitor (lisinopril): randomised, placebo controlled, crossover study [J].
Schrader, H ;
Stovner, LJ ;
Helde, G ;
Sand, T ;
Bovim, G .
BMJ-BRITISH MEDICAL JOURNAL, 2001, 322 (7277) :19-22
[30]   US valuation of the EQ-5D health states - Development and testing of the D1 valuation model [J].
Shaw, JW ;
Johnson, JA ;
Coons, SJ .
MEDICAL CARE, 2005, 43 (03) :203-220